Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

No cure exists for alopecia areata, and treatments are personalized.

IL-15 helps maintain hair growth and protects the immune status of hair follicles.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.

Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.

Particulate matter causes inflammation in hair cells, potentially harming hair growth.

Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.

Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.

SCD-153 shows promise as an effective topical treatment for alopecia areata.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.